Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Abramson Cancer Center at Penn Medicine
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Age over 18
Ability to provide informed consent
Ability to provide peripheral blood samples
Diagnosis of CLL
Indication(s) for CLL therapy
At least one criterion for high-risk disease
* Disease refractory (e.g., no response) to at least one round of chemotherapy
* Disease that has relapsed (i.e., returned) after at least one round of chemotherapy
* Proven presence of the 17p deletion within CLL cells
Planned receipt of idelalisib-rituximab as per FDA guidelines and patient's oncologists
You may not be if
Patients who do not meet the diagnostic criteria for CLL or at least one indication for treatment.
Patients who are receiving idelalisib with an off-label indication
Patients who do not or cannot provide informed consent to donate peripheral blood tumor samples to our stem cell core facility
Patients who do not provide informed consent to collect clinical, prognostic, and outcomes data during the time period that they are treated with idelalisib-rituximab
